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Background: Variability in probiotics manufacturing may affect their properties, with 
potential implications for their efficacy and safety. This is of particular concern with 
probiotic products destined for use in patients with serious medical conditions, including 
human immunodeficiency virus (HIV) infection. The purpose of the study was to carry out 
a series of experiments comparing the properties of the US-made probiotic formulation 
originally commercialized under the brand name VSL#3®, with those of the Italian-made 
formulation now commercialized under the same name. The US-made formulation 
has previously shown beneficial effects at the intestinal and neurological levels in HIV-
infected subjects as well as in patients with inflammatory bowel diseases and hepatic 
encephalopathy.
Methods: Eleven subjects receiving combined antiretroviral therapy for HIV-1 were 
treated for 6 months with the US-made VSL#3 formulation. At baseline and 6 months, 
T-cells were analyzed for phenotype and activation markers, and fecal samples were 
analyzed for bifidobacteria, lactobacilli, and their metabolites. The fecal metabolome 
was assessed using 1H-NMR spectroscopy. Production of metabolites of interest by 
bacteria obtained from sachets of the two formulations was compared in vitro and their 
effects on a rat intestinal epithelial cell line (IEC-6) were assessed. Particular attention 
was paid to the metabolite 1,3-dihydroxyacetone (DHA).
results: At 6 months, fecal samples showed a significant increase in the specific bac-
terial genera contained in the probiotic supplement. Immune activation was reduced 
as shown by a significant reduction in the percentage of CD4+CD38+HLA-DR+ T-cells 
at 6 months. Fecal concentrations of DHA decreased significantly. In vitro, significant 
differences in the production and metabolism of DHA were found between bacteria 
from the US-made and Italian-made formulations: the US-made formulation was able 
to metabolize DHA whereas the bacteria in the Italian-made formulation were producing 
DHA. DHA reduced the viability of Streptococcus thermophilus, reduced IEC-6 cell 
viability in a dose-dependent manner, and also led to a lower rate of repair to scratched 
IEC-6 cell monolayer.
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conclusion: Our data, in conjunction with previously published findings, confirm that 
the new Italian-made formulation of VSL#3® is different from the previous US-made 
VSL#3 and therefore its efficacy and safety in HIV-infected subjects is still unproven.
Keywords: human immunodeficiency virus, probiotics, metabolomics, gut, microbiota, Vsl#3
inTrODUcTiOn
Variability in the manufacturing of probiotics is an unexplored 
area that is of major concern for efficacy and safety, especially 
if the product is destined for use by individuals affected by seri-
ous conditions such as human immunodeficiency virus (HIV), 
inflammatory bowel disease (IBD), or cancer. Since bacterial 
gene expression is heavily affected by the growth media and by 
industrial processing parameters, modifications in the manufac-
turing unit, reagents, and know-how used can make the bacte-
rial strains more or less “probiotic” in their properties (1). The 
immunological and biochemical profile of the final product can 
be further modified by the fact that the bacteria are incorporated 
into numerous carrier matrices, which influence the bacterial 
metabolic pathways, especially short-chain fatty acid production 
and tryptophan metabolism (2, 3).
In the specific case of benefits from probiotic treatment 
observed in the intestinal tract and the central nervous system in 
patients receiving combined antiretroviral therapy (cART), the 
probiotic formulation produced at Dupont/Danisco in the US 
and containing the strains Lactobacillus plantarum DSM24730, 
Streptococcus thermophilus DSM24731, Bifidobacterium breve 
DSM24732, Lactobacillus paracasei DSM24733, Lactobacillus 
delbrueckii subsp. bulgaricus DSM24734, Lactobacillus aci-
dophilus DSM 24735, Bifidobacterium longum DSM24736, 
Bifidobacterium infantis DSM24737, can currently be considered 
the “reference formulation” because it is the formulation with 
which the most convincing efficacy and safety data were obtained 
(2–4). The human data are supported by observations in monkeys 
experimentally infected with Simian immunodeficiency virus 
(SIV) (5–7) and the same formulation is under evaluation in the 
multicenter trial ACTG A5350. However, this formulation is no 
longer commercially available under the brand name VSL#3® in 
Europe, Canada, or some other countries, and the brand name 
is now applied to a formulation manufactured at CSL/Nutrilinea 
in Italy. Because it comes from a different source, this new for-
mulation, although it is commercialized under the same VSL#3® 
trademark, might be not interchangeable with the formulation on 
which the efficacy and safety data are based.
When genetic or production changes occur, the need for 
reassessing efficacy and safety is mandatory. Unfortunately, while 
we have assays to understand probiotic physiology, the methods 
and tests causally linked to probiotic efficacy/safety in specific 
diseases are lacking. In this paper, we describe a new approach 
characterized by (a) the identification of the metabolites present 
in the feces of cART patients who had received 6 months’ treat-
ment with the “reference” (US-made) formulation, and then (b) 
the in  vitro comparison for production and metabolism of the 
same molecules by the US-made (the formulation administered 
to cART patients) and the new Italian-made VSL#3, and (c) their 
biological effects on a normal rat intestinal epithelial cell line. 
With this approach, rather than measuring probiotic viability at 
consumption and at excretion, we evaluated probiotic function 
at the site of action and identified some mechanisms by which 
genetic or physiological changes could affect the efficacy/safety 
of the formulation.
MaTerials anD MeThODs
The study was approved by the institutional review board 
(Department of Public Health and Infectious Diseases, Sapienza 
University of Rome; and the Ethics Committee of Umberto 
I General Hospital, Rome, protocol number 2970). All study 
participants signed written informed consent.
clinical study
Participants and Interventions
Eleven HIV-1 positive patients treated with cART and viro-
logically suppressed were recruited at the Department of Public 
Health and Infectious Diseases of Sapienza University of Rome, 
Italy. The inclusion criteria were: (i) to have signed the informed 
consent, (ii) men at least 18 years of age, (iii) receiving cART, (iv) 
with HIV-1 RNA < 37 copies/ml and CD4+ T counts > 400 cells/
mm3. Exclusion criteria were: (i) known or suspected allergy 
or intolerance to the specific probiotic formulation, (ii) use of 
probiotics or antibiotics during the 3 weeks prior to enrollment, 
(iii) drug addiction, (iv) history of or current inflammatory dis-
eases of the small or large intestine, (v) diarrhea, (vi) any current, 
past or systemic malignancy. All patients collected fecal samples 
prior to initiation (T0) and after 6  months (T6) of probiotic 
supplementation.
Patients received 1.8  ×  1012 live bacteria per day of the 
reference probiotic formulation (L. plantarum DSM24730, S. 
thermophilus DSM24731, B. breve DSM24732, L. paracasei 
DSM24733, L. delbrueckii subsp. bulgaricus DSM24734, L. acido-
philus DSM 24735, B. longum DSM24736, B. infantis DSM24737). 
This formulation manufactured at Danisco/Dupont (USA) was 
previously commercialized under the brand VSL#3®, but now is 
available under the brand Vivomixx® in Europe (Visbiome® in 
USA, DeSimone Formulation in Korea). It was not possible to 
treat any patient with the VSL#3 manufactured at CSL/Nutrilinea, 
Italy, since preliminary data have shown that the CSL/Nutrilinea 
made formulation increases the levels of p24 (+8%), contrary to 
the Danisco-made product which has an inhibitory activity (4%), 
and this is obviously ethically inacceptable (8).
T-Cell Phenotyping by Flow Cytometry
Phenotypes and activation markers were evaluated by Miltenyi 
Biotec flow cytometer-MACSQuant Analyzer (8 fluorescence 
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channels, three lasers) on freshly isolated peripheral blood mono-
nuclear cells. Immune activation was evaluated by multiparam-
eter flow cytofluorimetric analysis by the following anti-human 
monoclonal antibodies: CD3-PerCP, CD4-APC-Vio770, CD8-
FITC, CD45RO-PE-Vio770, CD27-VioBlue, CD38-APC, and 
HLA-DR-PE (Miltenyi Biotec, Bergisch Gladbach, Germany).
Virological Analysis
HIV-1 RNA copy numbers were evaluated in plasma prepared 
from blood obtained in EDTA-containing tubes and stored 
at −80°C. Levels of HIV-1 RNA were measured with Versant 
kPCR (Siemens Healthcare Diagnostic Inc., Tarrytown, NY, USA) 
with a detection limit of 37 copies/ml.
Fecal Specimen Processing to Assess  
Patient Compliance
Bacterial DNA from patients’ fecal samples was extracted using 
the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). 
Approximately 200  mg of feces were cut from frozen samples 
using a sterile disposable scalpel, resuspended in 1.4 ml of ASL 
lysis buffer from the stool kit, mixed with glass beads (150–
212 µm Sigma-Aldrich, St. Louis, MO, USA), and homogenized 
thoroughly. The suspension was incubated at 95°C for 5 min and 
DNA was purified according to the manufacturer’s instructions. 
DNA was eluted in 200 µl of AE buffer (provided in the kit) and 
stored at −20°C.
Real-time PCR Assay
Real-time PCR was used to quantify bifidobacteria and lacto-
bacilli using genus-specific primers and conditions described 
by Matsuki et al. (9) and by Stsepetova et al. (10), respectively. 
Briefly, PCR amplification and detection were performed on 
optical-grade 96-well plates using the Applied Biosystems 
7500 Real-Time PCR instrument (Applied Biosystems Inc., 
Norwalk, CT, USA). To quantify bifidobacteria and lactobacilli, 
the reaction mixture (25  µl) was composed of SensiMix SYBR 
Low-ROX (BIOLINE, Taunton, MA, USA), 500 nM primers for 
Bifidobacterium genus and 200 nM for Lactobacillus genus and 
2.5 µl of template DNA. The fluorescent products were detected 
at the last step of each of 40 cycles. A melting curve analysis was 
made after amplification to distinguish the targeted PCR product 
from the non-targeted PCR products. Standard curves were 
created using serial 10-fold dilutions of bacterial DNA extracted 
from B. breve and Lactobacillus brevis, respectively. All samples 




In order to study the fecal metabolome by NMR analysis, 80 mg 
of each fecal sample was vortex-mixed for 5  min with 1  ml of 
deionized water, followed by centrifugation for 15 min at 18,000 g 
at 4°C. 700 µl of the supernatant was added to 100 µl of a D2O 
solution of 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium 
salt (TSP) 10  mM, set at pH 7.00 with 1  M phosphate buffer. 
Before analysis, the samples were again centrifuged.
1H-NMR Spectra Acquisition
1H-NMR spectra were recorded at 298 K with an AVANCE III 
spectrometer (Bruker, Milan, Italy) operating at a frequency of 
600.13 MHz. The water residual signal was suppressed by pre-
saturation, while broad signals from slowly tumbling molecules 
were removed by including a CPMG (Carr-Purcell- Meiboom-
Gill) filter to a free induction decay sequence. The filter was 
made up by a train of 400 echoes separated by 0.8 ms, for a total 
time of 328  ms. Each spectrum was acquired by summing up 
256 transients using 32 K data points over a 7,211.54 Hz spectral 
(for an acquisition time of 2.27 s). In order to apply NMR as a 
quantitative technique (11), the recycle delay was set to 5 s, taking 
into consideration the longitudinal relaxation time of the protons 
under investigation.
Fecal Metabolome Data Analysis
The 1H-NMR spectra were adjusted for baseline irregulari-
ties as explained elsewhere (12). The signals were assigned by 
comparing their chemical shift and multiplicity with the Human 
Metabolome Database (13) and Chenomx software data bank 
(Chenomx Inc., Canada, version 8.1). Concentrations of mol-
ecules were calculated by employing the trimethylsilyl propionate 
(TSP) signal as an internal standard. In order to compensate for 
differences in dilution or solids content, all the spectra were nor-
malized by means of probabilistic quotient normalization (14). 
The concentration of the molecules was expressed as millimoles 
per gram of fecal sample. Statistically significant differences were 
assessed by means of paired Wilcoxon–Mann–Whitney tests for 
paired samples (p < 0.05). Samples were considered as outliers, 
and therefore excluded, when their concentration at T0, at T6 
or the T6 − T0 difference was outside 1.5 times the interquartile 
range (15).
comparative In Vitro analysis  
of the Probiotic Formulations
Samples of the US-made “reference” formulation (lot TM091, 
expiry date expiry date 9/10/2017) and the Italian-made for-
mulation (lot 512058, expiry date 12/2017) were utilized for the 
in vitro experiments. The bacterial strain content of the “refer-
ence” (US-made) formulation utilized in our trial is described 
in the Participants and interventions. The following strains: 
L. plantarum BP06, S. thermophilus BT01, B. breve BB02, 
L. paracasei BP07, L. delbrueckii subspecies bulgaricus BD08, 
L. acidophilus BA05, B. longum BL03, B. infantis BI04 are now 
instead present in the VSL#3® commercialized in Europe and 
Canada and are produced at CSL, Italy. According to Ferring 
Pharmaceuticals, distributor of the product, the strains present in 
the Italy-made product are identical to the strains present in the 
US-made product. We did not utilize the Italy-made formulation 
in our clinical trials.
Culture Conditions, Bacterial Cell Counts,  
and Metabolome Analysis
The sachets containing the two formulations were handled 
according to the manufacturers’ instructions and were opened 
immediately before the assay. The sachet contents were 
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suspended at 0.1% (w/v) in de Man, Rogosa and Sharpe (MRS) 
broth (Becton Dickinson and Company, Sparks, MD, USA), 
supplemented with 0.05% (w/v) l-cysteine. When indicated, 
inoculum was carried out in MRS broth 0.05% l-cysteine, added 
with 0.3  mmol/l or 0.6  mmol/l 1,3-dihydroxyacetone (DHA, 
Molbase Biotechnology, Shanghai, China). Bacterial suspensions 
were incubated at 37°C for 44 h in anaerobic jars supplemented 
with GazPack EZ (Becton Dickinson and Company). At the 
end of the incubation period, Lactobacillus and Bifidobacterium 
colony forming units (CFU) were determined by the plate 
count method on MRS agar plates; S. thermophilus CFU were 
determined analogously on M17 agar plates. The remaining 
cultures were centrifuged at 5,000 g for 10 min, then cell pellets 
were washed in sterile saline and resuspended in MRS medium 
supplemented with 10% glycerol, then frozen at −20°C; the 
supernatants were then filtered through a 0.2  µm membrane 
filter and stored at −20°C until NMR analysis. To study the 
metabolome of the probiotics, 1 ml of filtered supernatant was 
centrifuged for 15 min at 18,000 g and 4°C and then prepared 
for NMR analysis as described for the fecal metabolome. The 
molecular concentrations were expressed as millimoles per liter 
of culture medium.
iec-6 cell line and culture conditions
IEC-6 cell line (normal rat small intestine epithelial cells) pro-
vided by Sigma-Aldrich (St. Louis, MO, USA) were routinely 
monolayer-cultured in plastic culture flasks containing DMEM 
supplemented with 5% (v/v) fetal bovine serum, 0.1 IU/ml insu-
lin, 2 mM l-glutamine, 100 U/ml penicillin, and 100 µg/ml strep-
tomycin. After reaching 80% confluence, adherent cell cultures 
were expanded after previous detachment with trypsin solution 
from bovine pancreas. The well plates were incubated in sterile 
conditions at 37°C in a 5% CO2 humidified atmosphere and the 
complete medium was totally replaced every three days. For each 
experimental condition, IEC-6 cells were seeded within sterile 
12- or 24-well plates (Becton Dickinson, San Jose, CA, USA), at 
18,000 cells/cm2. At approximately 60% confluence, the cells were 
subjected to the different treatments. All culture reagents were 
acquired from Euroclone (Wetherby, West Yorkshire, UK). Cells 
were then incubated for 24 h with different DHA concentrations 
(0.1, 0.2, and 0.3  mmol/l) or with supernatants from bacterial 
suspensions grown for 44  h in presence or absence of 0.3 or 
0.6 mmol/l DHA (final dilution 1:2).
IEC-6 Cell Viability Assay
After incubation, the cells were washed with phosphate-buffered 
saline (PBS), collected and centrifuged for 10  min at 400  g. 
Pellets were resuspended and incubated for 5 min with Trypan 
blue solution (0.04%, final concentration). Cells were counted 
in a Bürker chamber by optical microscopy (Eclipse 50i, Nikon 
Corporation, Japan). The cell numbers and the percentage of live 
and dead cells were registered. Non-treated cells were processed 
as negative controls.
Contrast Phase Microscopy
IEC6 cells were seeded on rounded coverslips coated with 
poly-l-lysine 0.01% (Sigma-Aldrich) in distilled water. Stocks of 
1  g of each VSL#3 formulation (US-made reference version or 
Italian-made VSL#3) were suspended in 10 ml of PBS (Euroclone, 
Wetherby, West Yorkshire, UK) and added to IEC-6 cell line 
cultures at 1,000 bacterial cells/IEC-6 cell at 37°C. After 24  h, 
coverslips gently washed with PBS were first observed by contrast 
phase microscopy (Eclipse TS 100, Nikon Corporation, Japan) 
and then prepared for scanning electron microscopy (SEM) 
analysis, as described below.
Scanning Electron Microscopy Analysis
Stocks of 1 g of each VSL#3 formulation were suspended in 10 ml 
of PBS (Euroclone, Wetherby, West Yorkshire, UK). Bacteria were 
washed three times in PBS and then left to adhere for 1  h on 
rounded coverslips coated with Poly-l-Lysine 0.01% (Sigma-
Aldrich) in distilled water; coverslips were fixed with 2% glu-
taraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) 
in PBS for 30  min, then dehydrated by subsequent exchanges 
of the following ethanol gradual series: 30, 50, 70, 90, and 100% 
ethanol diluted in distilled water. Samples were successively 
dried by evaporation of hexamethyldisilazane (HMDS; Electron 
Microscopy Sciences, Hatfield, PA, USA): samples were immersed 
in 100% HMDS for 3 min after the 100% ethanol step, then the 
excess of HMDS was removed by absorption on filter paper and 
desiccated for 25 min. Coverslips were glued onto stubs, coated 
with gold in a SCD040 Balzer Sputterer, and observed using a 
Philips 505 SEM at 10–20 kV.
IEC6 cells were prepared for scanning electron microscopy 
(SEM) analysis as follows: coverslips were fixed with 2% gluta-
raldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in 
PBS for 30  min, then dehydrated by subsequent exchanges of 
the following ethanol gradual series: 30, 50, 70, 90, and 100% 
ethanol diluted in distilled water. Samples were successively 
dried by evaporation of hexamethyldisilazane (HMDS; Electron 
Microscopy Sciences, Hatfield, PA, USA): samples were immersed 
in 100% HMDS for 3 min after the 100% ethanol step, then the 
excess of HMDS was removed by absorption on filter paper and 
desiccated for 25 min (16). Samples were glued onto stubs, coated 
with gold in a SCD040 Balzer Sputterer, and observed using a 
Philips 505 SEM at 20 kV.
In Vitro Monolayer Wound Healing Assay  
and Image Processing Methods
IEC-6 cells were cultured in 12-well microplates under normal 
culture conditions and allowed to proliferate until ~90% conflu-
ence was reached, then DMEM was removed from the well and 
cell monolayers were scratched using a 200 µl pipet tip to create a 
uniform cell-free wound area with reproducible width of wound-
ing (0.7  mm). Debris was removed from the culture by gently 
washing with sterile PBS. Cell cultures were incubated for 24 h 
with fresh medium at 37°C in a 5% CO2 humidified atmosphere 
in the presence or absence of 0.3 mmol/l DHA. Non-treated cells 
were processed as negative controls.
Cell migration was monitored using an inverted microscope 
(Eclipse TS 100, Nikon) and photographed at different time 
intervals. At least three images for each condition were captured. 
To calculate the% closure of the wound, the images acquired for 
each sample (at least three measurements for each sample) were 
FigUre 1 | Bifidobacteria and lactobacilli in HIV-1 positive patients’ 
stools. Box and whisker plots based on log10 16S rRNA gene copies 
per gram stool. The horizontal line in the middle of each box represents 
the median, while the top and bottom borders represent the 75th and 
25th percentiles, respectively. The outliers are represented as individual 
points outside the boxes. Statistical tests were performed using paired 
t-test.
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further analyzed quantitatively using the stand-alone TScratch 
software that was developed to automatically analyze wound 
healing assays (17).
Statistical Analysis
Statistical analysis was performed using Prism 6.01 GraphPad 
Software, San Diego, CA, USA. In order to assess the normality 
of the distribution, Shapiro–Wilk test was performed. When 
data were not normally distributed, logarithmic transformation 
was performed and the statistical significance was determined 
by paired two-tailed Student’s t-test. Changes were considered 
statistically significant if p values were <0.05.
resUlTs
Participant Demographic and  
clinical characteristics
All study participants were HIV-1 positive Caucasian men. 
Median age was 41.8 years (IQR 22–53 years). They had been on 
cART for a median of 8 years (IQR 1.75–16.25 years). All subjects 
had been virologically suppressed (<37 HIV-1 RNA copies/ml) 
for at least 1  year and their median CD4+ cell count was 674 
(IQR, 564–824  cells/mm3) and 683 (IQR, 610–818  cells/mm3) 
cells/mm3 before and after supplementation with the reference 
formulation.
Participant compliance with Probiotic 
supplementation
The number of bifidobacteria and lactobacilli in fecal samples was 
assessed at enrollment (T0) and after 6 months of probiotic sup-
plementation (T6). At T6 there was a significant increase in the 
specific bacterial genera contained in the probiotic supplement 
compared with T0 (p < 0.05 for both), and this was assumed as 
proof that the participants had complied with the probiotic sup-
plementation (Figure 1).
changes in T-cell activation in Peripheral 
Blood after 6 Months of Probiotic 
supplementation
T-cell activation markers HLA-DR+ and CD38+ (CD38+HLA-DR+) 
were analyzed in CD4+ T-cell subsets from peripheral blood of 
the HIV-1 infected participants before and after supplementa-
tion with the US-made probiotic. The frequencies of CD4+ 
cells expressing simultaneously expressing HLA-DR and CD38 
significantly decreased after 6 months of supplementation with 
the US-made probiotic {CD4+ T-cells: [median 0.22 (IQR: 
0.10–0.39)] compared to T0 [median 0.63 (IQR: 0.35–2.09)]; 
p < 0.005}.
Virological analysis
HIV-1 RNA copy numbers after 6 months of probiotic supple-
mentation were confirmed to be persistently under 37 copies/ml, 
thereby excluding the possibility that the reference formulation 
probiotic has any facilitatory role for the replication of HIV in 
cART patients.
Probiotic Supplementation Reduces the Fecal 
Concentration of Six Molecules
Untargeted metabolomic analysis of the participants’ feces by 
1H-NMR led to the identification of 59 resolved signals pertain-
ing to different molecules with an intensity above the limit of 
quantification. Fifty-four were assigned mainly to amino acids 
and their derivatives, short-chain fatty acids, organic acids, and 
monomeric carbohydrates, while five could not be assigned. 
A paired comparison revealed that the concentrations of 10 
molecules were affected by the treatment, namely tryptophan, 
phenylalanine, tyramine, tyrosine, p-cresol, arabinose, 1,3-dihy-
droxyacetone, glycine, dimethylamine (DMA), and pyruvate. All 
molecules but tyrosine and p-cresol showed a decrease between 
T0 and T6, as detailed in Table 1.
The US-Made and Italian-Made Formulations Have a 
Different Capability to Produce and Metabolize DHA, 
which Affects S. thermophilus Viability
Each probiotic mix was cultivated up to the stationary phase of 
growth (44 h), then the metabolomic analysis was done on the 
bacterial supernatant, looking for the same metabolites (tryp-
tophan, phenylalanine, tyramine, tyrosine, p-cresol, arabinose, 
1,3-dihydroxyacetone, glycine, DMA, and pyruvate) that were 
found to be modified in the feces of participants after probiotic 
supplementation (Table 2).
Tyramine, p-cresol, arabinose, glycine, and DMA could 
not be identified in the studied samples. Both probiotic 
formulations showed similar concentrations of tryptophan, 
TaBle 3 | Concentration of 1,3-dihydroxyacetone (DHA) in US-made and Italian-
made probiotics culture supernatants.
Medium Us-made Vsl#3 italian-made 
Vsl#3
MRS + 0.3 mmol/l DHA 3.45 × 10−1 2.22 × 10−2 2.59 × 10−1
MRS + 0.6 mmol/l DHA 6.45 × 10−1 4.10 × 10−2 5.19 × 10−1
Concentration of DHA (millimoles per liter) in culture media MRS (4.46 × 10−2 mmol/l) 
added with 0.3 mmol/l or 0.6 mmol/l DHA after 44 h of incubation with US-made and 
Italian-made VSL#3.
TaBle 2 | Concentration of metabolites in VSL#3 culture supernatants.
Mrs Us-made italian-made
Tryptophan 9.26 × 10−1 8.19 × 10−1 8.71 × 10−1
Phenylalanine 4.26 4.51 4.21
Tyramine N.D. N.D. N.D.
Tyrosine 1.82 2.30 2.13
p-Cresol N.D. N.D. N.D.
Arabinose N.D. N.D. N.D.
1,3-Dihydroxyacetone 5.98 × 10−2 1.71 × 10−2 2.40 × 10−1
Glycine N.D. N.D. N.D.
Dimethylamine N.D. N.D. N.D.
Pyruvate 1.83 × 10−1 2.89 × 10−1 3.03 × 10−1
Concentration of the molecules identified by 1H-NMR in the VSL#3 supernatants after 
incubation in MRS medium for 44 h (millimoles per liter). Only the molecules found to 
be modified in the patients after the probiotic treatment are reported. In addition, the 
concentrations of these molecules in MRS prior to VSL#3 addition are reported.












Concentration of the molecules identified by 1H-NMR in the feces of subjects before 
(T0) and after 6 months of treatment (T6) with probiotics (millimoles per gram of feces). 
For clarity, only the molecules whose concentration was statistically affected (p < 0.05) 
by the treatment are reported.
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phenylalanine, tyrosine, and pyruvate at the end of the incu-
bation period. While the US-made “reference” formulation 
reduced the amount of DHA in the medium, the Italian-made 
formulation increased the amount of DHA detectable in the 
medium (Table 2).
To investigate the effects of DHA levels on the probiotic 
bacteria growth and metabolism, we repeated the experiments 
by adding exogenous DHA at two different concentrations, 
one comparable to the amount of DHA previously detected in 
the Italian-made supernatant (0.3  mmol/l) and the other cor-
responding to a doubled amount. The results confirmed that the 
US-made formulation was able to metabolize the DHA present 
in the culture medium, reducing its concentration by up to 
10−2 mmol/l in any experimental conditions; on the contrary, the 
Italian-made cultures were characterized by higher levels of DHA, 
significantly above the background of culture medium (Table 3). 
Furthermore, when DHA was added to the bacterial cultures 
at the concentration of 0.6  mmol/l, it significantly affected the 
viability of S. thermophilus present in the formulation, suggesting 
that any dietary intervention (probiotics, prebiotics, fermented 
foods, etc.) able to modify the host’s fecal metabolic profile in the 
direction of an increased DHA level, may impact on the growth 
and/or viability of certain bacterial populations, as previously 
reported for E. coli (Table 4).
Different Effects of the Two Formulations  
on IEC-6 Cells
IEC-6 cells were mixed with bacterial suspensions prepared from 
the two probiotic formulations at 1,000 bacterial cells/IEC-6 cell 
to highlight possible effects on morphology and cellularity. As 
evidenced by the phase contrast microscopic images shown in 
Figure  2, while the bacteria from US-made (reference) VSL#3 
did not affect morphology and cellular density of the monolayer, 
the addition of bacteria from Italian-made VSL#3 caused clear 
morphological cell damage and strongly reduced cellularity of 
the IEC-6 monolayer, thus confirming previously published data 
(18). SEM analysis of bacteria did not show significant differences 
between the formulations, although there was a greater tendency 
to aggregation of the bacteria from the US-made sachet, while 
bacteria from the Italian-made VSL#3 appeared mostly isolated 
(Figure 3). SEM observation of IEC-6 incubated for 24 h in the 
presence of VSL#3 showed that US-made bacteria were largely 
attached to cells (Figure 4A) with frequent cases of internaliza-
tion (Figure 4C). However, the Italian-made bacteria appeared 
mostly away from cells, with rare cases of membrane adhesion 
and internalization (Figures 4B,D).
Based on the results described above of the metabolomic 
analysis of the two formulations sold under the brand VSL#3, 
we also analyzed the effects of conditioned MRS medium from 
US- or Italian-made bacteria cultured for 44 h in the presence 
or absence of DHA at 0.3 or 0.6  mmol/l on IEC-6 cells after 
24 h incubation. Addition of conditioned MRS medium to the 
cell cultures at 1:2 dilution meant that original DHA concentra-
tions (0.3 or 0.6  mmol/l) were also diluted to obtain a final 
concentration of 0.15 or 0.3  mmol/l, respectively. As shown 
in Figure 5, while no evident effects could be observed in the 
cells incubated with conditioned MRS medium from US-made 
bacteria cultured in the absence (Figure  5A) or presence of 
DHA (Figures  5C,E), significant IEC-6 cell damage was evi-
dent in the samples treated with Italian-made bacteria cultured 
in the presence of DHA as compared to conditioned MRS 
medium without DHA addition (Figure 5B). In particular, in 
the cell cultures where the final virtual concentration of DHA 
was 0.15  mmol/l, the toxic effect was mainly evident on the 
periphery of wells (Figure 5D), while dramatic cell damage was 
extended to the whole wells where the final virtual concentra-
tion of DHA was 0.3 mmol/l (Figure 5F).
Based on these findings, we wanted to verify the potential 
in  vitro toxicity of DHA at different concentrations (0.1, 0.2, 
and 0.3 mmol/l) on IEC-6 cells after 24 h incubation. The rep-
resentative light microscopy images captured in both the center 
FigUre 2 | Effects in vitro of USA-made VSL#3 bacteria on IEC-6 cell cultures. IEC-6 cultures were mixed with bacterial suspensions prepared from US- and 
Italian-made VSL#3 at 1,000 bacterial cells/IEC-6 cell to highlight possible effects on morphology and cellularity after 24 h incubation at 37°C. The phase contrast 
microscopy images shown are representative of two independent experiments (magnification 10× or 20×).
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and periphery of plate wells (Figures 6A,B, respectively), showed 
DHA concentration-dependent cell damage and decrease in cell 
numbers that was more evident on the well periphery. The images 
from untreated cells (control) are also shown. In Figure 6C, the 
results of a cell viability assay with Trypan blue dye exclusion test 
expressed as the mean of duplicate values ± SD are shown. As 
expected, a dose-dependent decrease in viable IEC-6 cell number 
compared to control was evident at all DHA concentrations after 
24  h incubation. The inhibitory effect of DHA on IEC-6 cell 
growth, which was evident, even if not statistically significant, at 
0.1 mmol/l, appeared significantly different at higher concentra-
tions (0.2 and 0.3  mmol/l) when compared to untreated cells 
(p < 0.05 and p < 0.01, respectively).
The effect of 0.3 mmol/l DHA on the rate of scratched mon-
olayer closure was also analyzed and compared to the relative 
untreated cells at 0 h, as described in the Section “Materials and 
Methods.” The percentages of wound closure in untreated and 
DHA-treated cells were evaluated by observing the re-population 
of the area between the wound edges at different time points after 
the lesion (15 and 24 h). As shown in Figure 7A, the treatment 
with DHA led to a lower rate of monolayer repair with respect to 
untreated control, and this was statistically significant both after 
15 and 24 h (p < 0.05). Representative images from microscopic 
observations of scratched monolayers untreated or treated with 
DHA are shown in Figure 7B.
DiscUssiOn
Human immunodeficiency virus infection is characterized by 
a severe dysbiosis with a depletion of some beneficial bacteria, 
i.e., lactobacilli and bifidobacterial (19–21). Consequently, it has 
been suggested that the restoration of such species could some-
how contribute to the recovery of an adequate mucosal immune 
response and potentiate the antiviral defenses. In fact, it has 
recently been shown that vaginal lactobacilli are able to inhibit 
HIV-1 replication in human tissues ex vivo (22), and counteract 
infections by other sexually transmitted pathogens (23–26). In 
animal models, probiotics had a beneficial impact on mucosal 
health, enhancing local cellular and humoral immune defenses 
against HIV (27, 28). d’Ettorre et  al. have recently shown that 
supplementing cART with the probiotic formulation described in 
the current paper (the “reference” formulation) reduces systemic 
immune activation, and improves gut immune restoration and 
brain function (4).
However, not all probiotic formulations are effective and 
recommended for HIV patients. In a placebo-controlled clinical 
TaBle 4 | Effect of 1,3-dihydroxyacetone (DHA) on VSL#3 bacterial mixture viability.
Us-made Vsl#3 italian-made Vsl#3
Lactobacillus/Bifidobacterium S. thermophilus Lactobacillus/Bifidobacterium S. thermophilus
MRS 8.38 × 108 ± 1.49 × 108 1.01 × 109 ± 4.15 × 108 7.83 × 108 ± 2.02 × 108 1.08 × 109 ± 2.41 × 108
MRS + 0.3 mmol/l DHA 6.7 × 108 ± 2.22 × 108 8.1 × 108 ± 4.04 × 108 1.17 × 109 ± 4.74 × 108 9.08 × 108 ± 9.06 × 108
MRS + 0.6 mmol/l DHA 9.38 × 108 ± 6.52 × 108 5.9 × 108 ± 2.33 × 108 8.1 × 108 ± 6.7 × 108 6.5 × 108 ± 2.15 × 108*
Lactobacillus/Bifidobacterium, and S. thermophilus bacterial counts (CFU/ml) after 44 h of culture. US-made and Italian-made probiotic mixes were grown in MRS and MRS added 
with 0.3 mmol/l of 0.6 mmol/l DHA. Data are expressed as mean ± SD.
*p-Values < 0.05 (calculated by Student’s t-test).
FigUre 3 | Scanning electron microscopic analysis of bacteria from 
USA-made VSL#3. The images shown at different magnifications are 
representative of two independent analyses.
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study, cART patients taking a four-strain probiotic product for 
2 weeks failed to reduce their gastrointestinal symptoms notwith-
standing increased gut levels of Lactobacillus after the treatment 
(29). Haghighat and Crum-Cianflone identified 10 cases among 
HIV patients who developed lactobacillemia after probiotic sup-
plementation, suggesting the low count of CD4 T cells (<50 cells/
mm3) and altered integrity of the mucosal barrier as potential 
risks for systemic infection (30). Among the possible hypotheses 
for why some probiotic formulations are effective and others are 
ineffective, the role played by the manufacturing of the probiotic 
is rarely taken into consideration. The dogma that genetic identity 
results in identical safety and efficacy has been strongly challenged 
by Sanders et al. (1), who wrote that “growth conditions, growth 
substrates, cryoprotectants, food formulation, food processing 
conditions, and storage conditions may affect probiotic properties 
as scientists seek to optimize processes, viability, and function. Such 
modifications concomitantly may generate detectable differences in 
genes (mutations, genome rearrangements), gene expression pat-
terns, or metabolic output. This raises the question of when such 
changes warrant a re-examination of efficacy or safety.”
Even though, according to Ferring, the distributor of the 
VSL#3®, the strains present in the Italy-made product are identical 
to the strains present in the US-made product, recently, Cinque 
et al. have shown that the VSL#3 formulations manufactured in 
the US and Italy have a different effect on tumor cell lines and 
wound healing (18, 31). The same discrepancies between VSL#3 
formulations manufactured at different sites have been reported 
by Biagioli et al. in animal models of IBDs (32). These discrep-
ancies may have a major impact on patient safety and on the 
liability of doctors when they prescribe a probiotic formulation 
made with different processes at different production sites from 
the formulation, which generated the original evidence, without 
properly informing the patients.
In cART patients, a number of clinical studies conducted with 
the “reference formulation” (2–4) have reported beneficial effects 
at the intestinal and neurological levels, confirming and extend-
ing what previously observed in SIV-infected monkeys (5–7). 
This formulation is now no longer available in Europe, Canada, 
and some other countries under the VSL#3® brand, which instead 
is now applied to a different probiotic mix that is compared with 
the “reference formulation” in the work described here. The fact 
that the new formulation is now dairy-free means that the growth 
media for the bacterial strains have been changed, and the fact 
that the manufacturing has been moved from the US (Danisco/
Dupont) to Italy (CSL/Nutrilinea) may well have given rise to 
genome rearrangements, different gene expression patterns, or 
divergent metabolic output (1).
The data here reported confirm previously published reports 
of a reduction in immunoactivation after 6 months of treatment 
with the “reference formulation,” with a statistically significant 
reduction in the percentage of CD4+CD38+HLA-DR+ T-cells at 
6 months [median 0.22 (IQR: 0.10–0.39)] compared to baseline 
[median 0.63 (IQR: 0.35–2.09)]. These findings reinforce the 
concept on the beneficial impact of probiotic intervention with 
the US-made “reference formulation” on systemic immune acti-
vation in chronically HIV-1 infected patients. The viral load was 
persistently below 37 copies/ml, and this is an additional indicator 
of the formulation’s safety. No adverse events were registered, and 
notably at the end of the trial all the subjects expressed the desire 
to continue dietary supplementation with the same probiotic 
preparation because they experienced a subjective improvement 
of wellness, as previously documented (4).
The ability of the US-made (“reference formulation”) probi-
otic to restore lactobacilli and bifidobacteria was confirmed by 
a significant (p <  0.05) increase in these specific genera in the 
fecal samples of the patients at 6 months compared to baseline 
(Figure 1). Since the probiotic formulation administered to our 
patients contains metabolically active bacteria, we assumed that 
patients’ fecal metabolomic profile would have been changed at 
the end of the 6 months of treatment. Ascertained these modifica-
tions in the feces, the next step has been the evaluation of both 
formulations for their capacity to produce or metabolize the same 
molecules in vitro, and their biological effects.
Metabolomic analysis of the feces was then performed, on the 
assumption that being downstream of the genome, transcriptome, 
and proteome, the metabolome would be the best representation 
of the microbiota phenotype, and that changes in individual 
FigUre 4 | Scanning electron microscopic analysis of IEC-6 cell cultures treated with USA-made VSL#3 bacterial suspension. IEC6 cells were seeded on rounded 
coverslips coated with Poly-l-Lysine. US- or Italian-made VSL#3 resuspended in phosphate-buffered saline were added to IEC-6 cell line cultures at 1,000 bacterial 
cells/IEC-6 cell at 37°C for 24 h. The images shown are representative of two independent experiments. (a,c) Representative images of IEC-6 treated with 
US-made bacteria. (B,D) Representative images of IEC-6 treated with Italian-made bacteria. Arrows indicate the integration process of bacteria from US-product on 
cell surface which was not observed with bacteria from the Italian-made formulation.
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metabolites might be significant even in case of small changes 
on metabolic fluxes, due to cascade or feedback effects. Out of 
54 assigned molecules, mainly pertaining to the classes of amino 
acids, organic acids and carbohydrates identified in the feces of 
the patients, we focused our attention on tryptophan, phenyla-
lanine, tyramine, tyrosine, p-cresol, arabinose, 1,3-dihydroxy-
acetone, glycine, DMA, and pyruvate, which were significantly 
affected by the 6 months of probiotic supplementation (Table 1). 
Special attention was paid to DHA, a triose sugar generated from 
fructose-1-phosphate and fructose-1,6-diphosphate catalyzed 
by aldolase B activity (33). The reduction in DHA in the feces 
after the probiotic treatment was considered one of the signs of 
an amelioration of the patients’ gut microbiota, in light of the 
fact that DHA has been shown to be mutagenic in the Salmonella 
mutagenicity assay and an inducer of DNA damage (34, 35). When 
DHA accumulates, it indicates an alteration of the glycolytic 
pathways, and it tends to react with proteins by the Maillard-type 
reaction, inducing DNA damage, apoptosis, and cell-cycle block 
(36). Further studies were also carried out on other molecules of 
interest, and will be published separately.
The next step was aimed at assessing whether both probiotic 
formulations may produce or metabolize DHA when cultivated 
up to the stationary phase of growth (44 h), and the influence of 
DHA on the bacterial cells during the fermentation when it is 
exogenously added. Our in vitro experiments confirm the capa-
bility of the US-made VSL#3 to metabolize DHA, as reflected by 
a reduced concentration of this metabolite in the culture medium 
(Table  2), confirming what was observed in feces from cART 
patients after a 6 months’ treatment. This metabolic feature was 
not evidenced for the Italian-made product, which on the con-
trary produced significantly higher levels of DHA. Interestingly, 
when DHA was added to the bacterial cell cultures, a significant 
(p < 0.05) decrease in S. thermophilus viability was observed and 
this may alter the biochemical and immunological characteristics 
of the formulation (Table 4). Previously, Cinque et al. have shown 
that the Italian-made VSL#3 contains approximately 130% more 
dead bacteria than the US-made VSL#3 (31). According to our 
data, one of the causes for the reduced viability of the bacterial 
cells present in the Italian-made product is the presence of strains 
which synthesize DHA, depending on gene expression in differ-
ent culture media and the production processes of the strains at 
CSL, and which antagonize the survival of other bacterial species, 
in the specific case S. thermophilus.
To clarify what the impact would be of probiotic supple-
mentation that increases DHA levels in the gut, we decided to 
add the supernatant from the two probiotic products to IEC-6 
cells. While the US-made VSL#3 did not affect the morphology 
and cellular density of the IEC-6 monolayer, the Italian-made 
FigUre 5 | Effects in vitro of conditioned medium from USA-made VSL#3 bacteria grown for 44 h in presence or absence of 0.3 or 0.6 mmol/l 
1,3-dihydroxyacetone (DHA) on IEC-6 cell cultures for 24 h (final dilution of conditioned medium on cell cultures: 1:2). (a,B) Cells treated with conditioned medium 
from US- or Italian-made VSL#, respectively. (c,D) Cells treated with conditioned medium from US- and Italian-made VSL#3 grown with 0.3 mmol/l DHA, 
respectively. (e,F) Cells treated with conditioned medium from US- and Italian-made VSL#3 grown with 0.6 mmol/l DHA, respectively. An image of untreated cells 
(Control) is also shown. The phase contrast microscopy images shown (10× magnification) are representative of two independent experiments.
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product strongly reduced the viability of the IEC-6 monolayer, 
thus reconfirming previously published data (18). SEM analysis 
did not evidence significant differences between US- or Italian-
made VSL#3, although there was a greater tendency to aggrega-
tion in bacteria from the US-made formulation. Moreover, SEM 
also showed that the US-made bacteria showed greater ability to 
adhere to IEC-6 cells. Considering that the non-specific binding 
of probiotic bacteria to cell wall constituents has been recently 
hypothesized as a potential mechanism underlying the ability 
of probiotics to block the accessibility of pathogen agents (37), 
the differences we have observed between the two bacterial 
formulations, although they require further investigation, appear 
intriguing.
Finally, in an attempt to link the presence of certain levels of 
DHA to the observed cellular damage, conditioned MRS medium 
from US- or Italian-made bacteria cultured in the presence or 
absence of DHA was added to the IEC-6 cells. DHA dose-
dependent cell damage was observed in the cultures incubated 
with Italian-made VSL#3, while no effects could be observed with 
conditioned MRS medium from the US-made product cultured 
in the absence or presence of DHA. The DHA concentration-
dependent cell damage and a slower wound healing process in 
scratched monolayer observed in our study is in accord with 
previously published data suggesting that DHA and short-chain 
trioses react with proteins by Maillard-type reaction thus induc-
ing DNA damage, cell-cycle block, and apoptosis (35, 36, 38).
Usually, what it is detected in  vitro may not be necessarily 
translate in the in  vivo environment, but in this case it is the 
clinical improvement observed in the patients treated with the 
US-made VSL#3 and the concomitant reduction of the amount of 
fecal DHA that strength the in vitro observations. The dysruption 
of an appropriate mucosal barrier function and a perturbation of 
the immune response could be the related to some extent to an 
abnormal DHA production and metabolization. Considering the 
chronic intestinal epithelial damage and alterations in the profile 
of the fecal flora of HIV+ subjects, the above in vitro observations 
are therefore clinically relevant and raise concerns about the Italy-
made VSL#3, confirming what anticipated in animal models of 
IBD by Biagioli et al. (32).
In conclusion, we have set up a new method to confirm the 
biosimilarity and interchangeability between different probiotic 
formulations especially if aimed at the dietary management of 
serious medical conditions. This is an area of research still unex-
plored but with potential serious implications for the health of 
the patients. In the specific case of the VSL#3 product, according 
to our data and previously published findings (18, 31, 32), the 
FigUre 6 | Effects in vitro of 1,3-dihydroxyacetone (DHA) on IEC-6 cell cultures. IEC-6 cells were incubated with different concentrations of DHA (0.1, 0.2, and 
0.3 mmol/l) for 24 h incubation at 37°C. Phase contrast microscopy representative images of the cells at the center of the well (a) and at the periphery (B) are 
shown (10× magnification). (c) Effect of DHA on cell viability assessed by Trypan blue dye exclusion. The results are expressed as mean values of duplicates ± SD. 
*p < 0.05; **p < 0.01; ***p < 0.001. The results are representative of two independent experiments.
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FigUre 7 | Effects of 1,3-dihydroxyacetone (DHA) on scratched monolayer wound healing of IEC-6. (a) The effect of DHA (0.3 mmol/l) on the closure rate of 
scratched monolayers was analyzed and compared to control cells. The microscopy images acquired for each sample were analyzed with TScratch software to 
automatically quantify the percentage of wound closure. Data are presented as the mean of duplicates ± SD and are relative to% wound closure versus T0 at 15 
and 24 h from monolayer scratching, as indicated. The results are representative of two independent experiments (*p < 0.05; **p < 0.01). (B) Representative 
microscopy images (10× magnification) of all cell culture conditions are shown.
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